Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK
New York, Jan 10, 2026, 14:37 EST — Market closed Merck & Co (MRK) closed Friday 0.4% lower at $110.53 following reports that the pharmaceutical giant is negotiating to acquire cancer drug developer Revolution Medicines in a deal valued between $28 billion and $32 billion. (Reuters) Timing is crucial. As Merck faces patent losses on its blockbuster cancer drug Keytruda later this decade, it’s searching for new growth drivers. A deal of this magnitude would sharply indicate just how aggressive the company intends to get. The week also arrives with investors gearing up for policy turbulence tied to vaccines and